0001739614-22-000105.txt : 20221005 0001739614-22-000105.hdr.sgml : 20221005 20221005161552 ACCESSION NUMBER: 0001739614-22-000105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221004 FILED AS OF DATE: 20221005 DATE AS OF CHANGE: 20221005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eckelman Brendan P. CENTRAL INDEX KEY: 0001766433 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 221295770 MAIL ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eckelman Living Trust Dated February 5, 2014 CENTRAL INDEX KEY: 0001821294 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 221295768 BUSINESS ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11099 TORREY PINES ROAD, SUITE 280 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-759-1499 MAIL ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11099 TORREY PINES ROAD, SUITE 280 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 wf-form4_166500090831812.xml FORM 4 X0306 4 2022-10-04 0 0001739614 Inhibrx, Inc. INBX 0001766433 Eckelman Brendan P. C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 0 1 0 0 Chief Scientific Officer 0001821294 Eckelman Living Trust Dated February 5, 2014 C/O INHIBRX, INC. 11025 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 0 0 1 0 Common Stock 2022-10-04 4 S 0 1448 24.6688 D 2274105 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 6207 26.0614 D 2267898 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 11136 26.7764 D 2256762 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 4262 27.7566 D 2252500 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 5954 28.9713 D 2246546 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 10893 29.6798 D 2235653 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 2022-10-04 4 S 0 100 30.52 D 2235553 I By the Eckelman Living Trust dated February 5, 2014 Common Stock 160000 I By trust Common Stock 160000 I By trust The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014. The shares were sold in multiple transactions at prices ranging from $24.23 to $25.20, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014. The shares were sold in multiple transactions at prices ranging from $25.35 to $26.33, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.32, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold in multiple transactions at prices ranging from $27.35 to $28.33, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold in multiple transactions at prices ranging from $28.35 to $29.34, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold in multiple transactions at prices ranging from $29.40 to $30.23, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. /s/ Kelly D. Deck, attorney-in-fact 2022-10-05